RPS Pharma Scene #9 - Kindeva
With Laura Walsh, John Vasilakos and Lisa Dick
This episode, Professor Gino Martini is joined by representatives from Kindeva Drug Delivery.
Kindeva develops and manufactures complex drug device combination products, with a focus on transdermal and inhalation drug delivery products.
Gino welcomes Laura Walsh from Global Buisness Development, Dr. John Vasilakos, Global Head of MTS at Kindeva, and Lisa Dick, the leading platform scientist for microneedles.
Kindeva originated as Riker Labatories, who invented the first metered-dose inhaler in 1956, before becoming pat of 3M.
Now, Laura, John and Lisa talk about Kindeva's microneedle technology, the impact of COVID-19, and other technologies.
Laura Walsh is a Business Development Manager with over 25 years’ experience in the drug delivery business in both Key Account Management and New Business Development.
Laura has a background in inhaled drug delivery and also now leads our transdermal business development activities globally. Laura also plays the leading role in Europe for our intradermal business having been involved with Kindeva’s microneedle platform for more than 10 years.
Laura also plays the leading role in Europe for our intradermal business having been involved with Kindeva’s microneedle platform for more than 10 years.
Dr John Vasilakos is Global Head of MTS Business Development and Senior Research Immunologist at Kindeva in the USA.
John has over 26 years in the pharmaceutical and biotechnology industry, which includes public and privately held large and small pharmaceutical, drug delivery, and biotechnology companies.
In this podcast, John goes into some of the history of Kindeva and the focus on transdermal and inhalation drug delivery products.
Lisa Dick, PhD is a Scientist with Kindeva Drug Delivery in the USA, where she leads the Microstructured Transdermal System team for microneedles from the technical perspective.
In her 20 years within the pharmaceutical field, she has previously contributed to the development of inhalation and transdermal drug products from early-phase feasibility through launch and marketed product support.
She has extensive experience with drug product development, materials, including extractables and leachables, quality, and contributes to regulatory filings. She received her PhD in chemistry from Northwestern University and did postdoctoral training at Princeton University.